achieving very low ldl-c levels with the pcsk9 inhibitor evolocumab
Published 6 years ago • 1.3K plays • Length 3:26Download video MP4
Download video MP3
Similar videos
-
4:24
repatha: pcsk9 inhibitor use/development & very low ldl levels
-
52:04
a real world approach to ldl cholesterol using pcsk9 inhibitors, october 5 2018
-
5:13
safety and tolerability of very low ldl levels in patients treated with 52 weeks of evolocumab
-
26:59
optimizing ldl-c lowering with pcsk9 inhibition
-
3:26
prof john chapman: physiological implications of very low ldl cholesterol levels
-
1:12
prof. s. nicholls: patient progress despite very low ldl cholesterol levels on a pcsk9 inhibitor
-
1:05:30
pcsk9 inhibition: lowering lipids and reducing cardiovascular events
-
2:14
fourier: use of pcsk9 inhibitor evolocumab - acc.17
-
0:44
what is a pcsk9 inhibitor? #pcsk9 #repatha #praluent #inclisarin #cholesterol
-
58:08
the cholesterol wars: identifying patients who would most benefit from pcsk9 inhibitors (part 1)
-
![[complex pci 2021] ldl-c management with evolocumab in acs patients -it’s time to act!](https://i.ytimg.com/vi/eNAmSx5IzHU/mqdefault.jpg)
1:01:30
[complex pci 2021] ldl-c management with evolocumab in acs patients -it’s time to act!
-
2:44
derick raal discusses the safety of very low ldl cholesterol
-
1:28
safety and efficacy of very low ldl-c (fourier-ole trial)
-
3:05
lowering ldl-c: how low and for how long? | professor evan stein
-
46:28
ldl-c: how low should we go?
-
1:37:52
novel therapeutic strategies targeting pcsk9 for reducing ldl-c in hyperlipidemia and ascvd
-
5:47
approval of pcsk9 inhibitors still leaves some questions
-
11:56
emergence of pcsk9 inhibitors
-
2:31
what are pcsk9 inhibitors? (new lipid lowering drugs)